Department of Neurology and Psychiatry, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Department of Otorhinolaryngology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Neurol Sci. 2022 Feb;43(2):799-809. doi: 10.1007/s10072-021-05740-y. Epub 2021 Nov 17.
COVID-19 is a pandemic disease which predominantly affects the respiratory system with high critical care mortality and morbidity; however, it also causes multi-organ dysfunction in a subset of patients. Although causality between COVID-19 and mucormycosis remains unclear, many factors including glucocorticoids, worsening of blood glucose control, and viral-induced lymphopenia have been attributed to cause mucormycosis in patients with COVID-19. In COVID-19 patients, especially those who need oxygen support, inflammatory and cytokine storm or usage of steroids make the immune system weak. This may pave the way for opportunistic infections including mucormycosis. We report fourteen cases of COVID-19 infection, who developed rhino-orbito-cerebral mucormycosis, during treatment. Early recognition of this life-threatening infection is the key to allow for optimal treatment and improved outcomes.
新型冠状病毒肺炎(COVID-19)是一种主要影响呼吸系统的流行疾病,具有较高的重症监护死亡率和发病率;然而,它也会导致一部分患者多器官功能障碍。虽然 COVID-19 和毛霉菌病之间的因果关系尚不清楚,但许多因素,包括糖皮质激素、血糖控制恶化和病毒诱导的淋巴细胞减少,都被认为是 COVID-19 患者发生毛霉菌病的原因。在 COVID-19 患者中,特别是那些需要吸氧支持的患者,炎症和细胞因子风暴或使用类固醇会使免疫系统减弱。这可能为包括毛霉菌病在内的机会性感染铺平道路。我们报告了 14 例 COVID-19 感染患者,他们在治疗过程中发生了鼻-眶-脑毛霉菌病。早期识别这种危及生命的感染是实现最佳治疗和改善预后的关键。